Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRESENT: Pemafibrate for NAFLD with Hypertriglyceridemia
NCT06623539Phase 2Active, not recruiting
- Sponsor
- Yokohama City University
- Start
- Dec 2020
- Primary completion
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of pemafibrate in non-alcoholic fatty liver disease (NAFLD) (3 arms), sponsored by Yokohama City University. Primary endpoint: Change in Alanine Aminotransferase Level at 24 weeks. Started Dec 2020; status: active, not recruiting.
02
Drugs
pemafibrate
03
Conditions
non-alcoholic fatty liver disease (NAFLD)
Beyond the preview
Go deeper on NCT06623539.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06623539.